[Development of Oncolytic Virus Immunotherapy to Improve the Immunosuppressive Microenvironment in Pancreatic Cancer].
Immunotherapy resistance in pancreatic ductal adenocarcinoma(PDAC)limits treatment outcomes; therefore, improving the immunosuppressive microenvironment is important for PDAC treatment. We developed an oncolytic adenovirus, OBP-702, carrying the tumor suppressor gene p53, and report its therapeutic potential to induce cytopathic effects and activate antitumor immunity via p53 induction. In the present study, we investigated the therapeutic potential of epigenetic modulators in oncolytic viral immunotherapy combined with a dendritic cell vaccine.
Authors
- Hiroshi Tazawa (ORCID: https://orcid.org/0000-0003-4658-1050)
- Kanto Suemori
- Shinji Kuroda (ORCID: https://orcid.org/0000-0003-3100-8243)
- Satoru Kikuchi (ORCID: https://orcid.org/0000-0002-7671-0696)
- Shunsuke Kagawa (ORCID: https://orcid.org/0000-0002-3610-8211)
- Toshiyoshi Fujiwara (ORCID: https://orcid.org/0000-0002-5377-6051)
- Kazuhiro Noma (ORCID: https://orcid.org/0000-0002-5584-3908)
- Motohiko Yamada (ORCID: https://orcid.org/0000-0003-3451-335X)
- Naohiro Okada
- Yasuo Urata
Institutions
- Okayama University (JP)
Publication Details
- Journal
- PubMed
- Published
- 2025-05-01
- Primary Topic
- Virus-based gene therapy research
- Type
- article